Brief: Brii Biosciences Says Its Majority-Owned JV Began Phase 2 Clinical Trial For Covid-19 Neutralizing Antibodies
20/07/2021 15:24
July 20 (Reuters) - Brii Biosciences Ltd 2137.HK :
* MAJORITY-OWNED JV OF CO BEGAN PHASE 2 CLINICAL TRIAL IN
PRC FOR
SEVERE ACUTE RESPIRATORY SYNDROME COVID-19 NEUTRALIZING
ANTIBODIES
Further company coverage: 2137.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Brii Biosciences
See all newsBrief: BRII Biosciences Discloses Launch Of BRISC, An SIRNA Therapeutics Discovery Platform
China's Brii Biosciences interim net loss narrows on lower R&D expenses
Brief: Brii Biosciences Announces Share Buy-Back Programme No More Than HK$60 Million
Brief: Brii Biosciences Says Arbitration Between Brii And Vir Remains In Early Stages With No Resolution
Brief: Brii Biosciences Submits Demand For Arbitration Against VIR